Background: Ablation of complex fractionated atrial electrograms (CFAE) is now performed in patients with persistent atrial fibrillation (AF). However, extensive ablation is often necessary to eliminate all CFAE or to terminate AF. The purpose of this study was to evaluate the effects of antiarrhythmic drugs (AAD) on CFAE.
Introduction
Pulmonary vein (PV) isolation is effective for treating paroxysmal atrial fibrillation (AF), 1, 2) but is not enough to cure persistent AF. 3) To improve the clinical outcome, extensive ablation, including ablation of complex fractionated atrial electrograms (CFAE) and multiple linear lesions, has been widely adopted, particularly in patients with persistent AF. [4] [5] [6] [7] [8] [9] CFAE are sometimes recorded over diffuse areas and numerous ablation applications are often necessary to eliminate all CFAE or to terminate AF. It is also difficult to distinguish culprit CFAE (e.g. CFAE associated with perpetuating AF) from bystander CFAE. Although the most robust endpoint may be termination of AF, this generally requires a very long procedure. 7) Furthermore, extensive ablation is associated with procedural complications, proarrhythmia, 6) and stroke risk, and may compromise atrial mechanical function. 10) To minimize the extent of ablation required, we use antiarrhythmic drugs before CFAE ablation in persistent AF. However, it is unclear whether ablation of only CFAE localized with a drug is sufficient for a desirable outcome. Therefore, we conducted this study to evaluate the effects of a pure Na þ channel blocker or a pure I Kr channel blocker on CFAE and to determine whether ablation of only CFAE localized with a drug is sufficient for clinical efficacy.
Methods

Patient characteristics
The study population consisted of 60 consecutive patients (56 men and 4 women; mean age 56 AE 10 years old) with persistent (n ¼ 22) and longstanding persistent AF (n ¼ 38) who were referred for catheter ablation guided by NavX system (NavX, with CFE software, St. Jude Medical, Minnetonka, MN, USA). Persistent AF was defined as AF that was sustained for more than seven days (mean, 6 AE 2 months; range, 3 to 10 months) but which required pharmacologic or electrical cardioversion. Longstanding persistent AF was defined as continuous AF that had lasted for more than one year (mean, 59 AE 45 months; range, 12 to 120 months). The mean LA diameter was 45 AE 5 mm, the mean LA volume was 68 AE 20 ml, and the mean ejection fraction was 59 AE 8%, as determined by echocardiography. The mean LA appendage flow was 48 AE 14 cm/sec, as determined by transesophageal echocardiography. A mean of 2 AE 1 anti-arrhythmic drugs had been administered, but failed to maintain a normal sinus rhythm. None of the patients had been treated with amiodarone within the 6 months preceding the procedure. No structural heart disease was present in 26 patients. Hypertension was present in 31 patients and coronary artery disease was documented in four. The patients were randomly assigned to receive pilsicainide (n ¼ 30) or nifekalant (n ¼ 30). There were no significant differences in the patient characteristics or substrate properties between the two groups ( Table 1) . Patients who showed spontaneous termination of AF during or just after box isolation or who had organized AF with little CFAEs after box isolation were excluded from the study.
Electrophysiological study
Written informed consent was obtained from all patients. The patients received oral anticoagulants for at least 2 months before ablation. Transesophageal echocardiography was performed to exclude any LA thrombi before ablation. Antiarrhythmic drugs were discontinued five half-lives before ablation. Two 5-Fr quadripolar electrode catheters (St. Jude Medical, Minnetonka, MN, USA) were placed in the high right atrium and coronary sinus. Triple transseptal punctures were performed, and three 8-Fr SL0 sheaths (St. Jude Medical, Minnetonka, MN, USA) were advanced into the LA. During the procedure, heparinization was continued to maintain an activated clotting time of 350-450 seconds. The surface electrocardiograms (ECG) and bipolar endocardial electrograms were continuously monitored and stored on a computerbased digital amplifier/recorder system for offline analysis (LabSystemÔ PRO, Bard Electrophysiology, Lowell, MA, USA). The intracardiac electrograms were filtered from 30 to 500 Hz and measured at a sweep rate of 200 mm/s. Atrial pacing was performed using a programmed stimulator (SEC-3102, Nihon Kohden, Tokyo, Japan). Two decapolar ring catheters (Lasso, Biosense-Webster, Diamond Bar, CA, USA) were inserted into the LA and used for the mapping of PVs. A deflectable, 7-Fr ablation catheter (Cool path duo, St. Jude Medical, Minnetonka, MN, USA) was also inserted into the LA for mapping and ablation. A 3D geometry of the LA was created using the NavX system.
Box isolation
Ablation was performed during AF with an irrigated-tip 4-mm ablation catheter. Radiofrequency energy was delivered at a power of 30-40 W. The temperature was limited to 40 C. The luminal esophageal temperature was monitored with a catheter in the esophagus close to the tip of the ablation catheter. During ablation at the posterior LA close to the esophagus, cooling water was infused into the esophagus through a tube just above the catheter and ablation was performed at a maximum power of 30 W and a temperature of 40 C. If the esophageal temperature was higher than 38 C, RF applications were interrupted. Radiofrequency energy was delivered for 30 seconds at each point.
Continuous lesions at the anterior portions of the ipsilateral superior and inferior PVs were initially created under guidance of a Lasso catheter and the NavX system. Ablation was started at the superior wall and continued around the anterior and inferior venous perimeter. At the posterior portions of the PVs, ablation was sequentially targeted to antral segments with the earliest activity until PV isolation was achieved.
Ablation of the LA roof was then performed by creating a contiguous line of ablation lesions to join the superior PVs. Finally, ablation of the LA floor was performed by creating a contiguous line of ablation lesions that joined the inferior PVs to isolate the posterior LA. The entrance block of a box lesion during AF was confirmed by the elimination of PV and posterior LA potentials using a circular mapping catheter.
Mapping of CFAE
After box isolation, CFAE mapping was performed using a 4-mm-tip catheter during AF by point-to-point contact mapping. Regarding the mapping sites for analysis, these were nearly equally distributed in the LA, and the sampling sites were collected from each of the subanatomical regions of the LA except the box region, i.e., the anterior LA, septal LA, anterior roof, inferior LA, lateral LA, around the mitral annulus, and the LA appendage region. In each region, at least 20 points were determined. The points in each region were similar in number and were nearly equally distributed. The NavX mapping parameters were set to ''CFE-mean,'' which is an interval-analysis algorithm that produces a color map that is representative of the CFAE distribution. The CFAEs were characterized by cycle-length values obtained from each site using a recording duration of 6 seconds. This duration was determined based on Lin's 11) report that the assessment of fractionated electrograms required a recording duration of !5 seconds at each site to obtain a consistent fractionation. The parameters of the automatic algorithm for CFAEs have been described previously. According to the criteria proposed by Nademanee et al., 5) CFAEs were defined as fractionated electrograms composed of two or more deflections with a mean cycle length 120 ms. Non-CFAEs were defined as having a mean cycle length of >120 ms.
Antiarrhythmic drugs
After complete CFAE mapping, pilsicainide (1 mg/kg) or nifekalant (0.3 mg/kg) was administered over 5 minutes. After drug administration, the CFAE map was created again. The mean AF cycle length at the coronary sinus, the maximal CFAE (shortest cycle length), the mean degree of CFAE, and the proportion of CFAEs in the LA (% of LA with a mean cycle length <120 ms) were compared before and after drug administration.
Ablation of CFAE localized by antiarrhythmic drugs
After re-mapping, ablation of CFAE localized by the drug was performed. The endpoint of CFAE ablation was the elimination of all identifiable target electrograms or termination of AF. If AF became organized during ablation, mapping and ablation were performed to terminate the organized tachycardia. If the patient remained in AF despite the elimination of all visible CFAE, electrical cardioversion was performed to restore sinus rhythm. During sinus rhythm, exit block of the box lesion was confirmed. Gaps along the ablation lines were detected and closed using high voltage (10 V) pace mapping through the ablation catheter. With lack of LA capture, the line was considered as complete at this location. In case of LA capture, a gap was suspected and RF energy was delivered simultaneously while pacing from the tip of the ablation catheter. The endpoint of box isolation was defined as bidirectional conduction block, that is both lack of potentials in box and lack of LA capture. AF induction was not performed.
Post-ablation care and follow-up
Intravenous heparin was administered to all patients for 24 hours after the procedure, followed by warfarin for 3 months. After the ablation, all antiarrhythmic drugs were prescribed for 2 months to prevent the early recurrence of AF. Surface ECG, transthoracic echocardiography, and 24-hour Holter recording were performed the day after the procedure, and repeated at 1, 3, 6, and 12 months. All patients were provided with a telemetry ECG recorder (Omron HCG-801, Kyoto, Japan) for one month at 6 months after ablation to document symptomatic episodes or to record an ECG once per week if asymptomatic. AF recurrence was defined as an episode that lasted more than 1 minute and that was confirmed by ECGs 2 months after ablation (blanking period). In the event of recurrent symptomatic or asymptomatic arrhythmias, the patients were offered an additional ablation after a trial of drug therapy.
Statistical analysis
All of the statistical analyses were performed using the SAS (Statistical Analysis System) Software Package (Ver. 9.2, SAS Institute Inc., Cary, NC). Categorical variables were compared between groups by a 2 analysis with a Fisher's exact test. Continuous variables were compared between groups by the Student's t-test or Wilcoxon ranksum test. Data are presented as the mean AE SD. Changes in the substrate properties before and after drug administration were examined by the Wilcoxon signed-rank test. Statistical significance was set at a P value less than 0.05.
Results
Effects of antiarrhythmic drugs on persistent AF
After box isolation, pilsicainide terminated AF in 2 patients (AF converted to sinus rhythm in 1 and perimitral flutter in 1) and nifekalant terminated AF in 10 patients (AF converted to sinus rhythm in 7, perimitral flutter in 2, and typical flutter in 1). Nifekalant had a greater effect on AF termination than pilsicainide (P ¼ 0:01) ( Table 1 ). In these patients, re-mapping of CFAE and additional ablation of CFAE could not be performed, and therefore, these 12 patients were excluded from subsequent analysis of the effects of antiarrhythmic drugs on CFAE characteristics.
Effects of antiarrhythmic drugs on CFAE
In 48 patients without AF termination, the LA substrate characteristics were assessed before and after the administration of antiarrhythmic drugs. As shown in Table 2 and Figure 1 , the LA substrate was significantly less fractionated in terms of the maximal CFAE (shortest cycle length), mean degree of CFAE, and proportion of CFAE after both antiarrhythmic drugs. There were no significant differences in these substrate factors between pilsicainide and nifekalant before and after administration.
The spatial distribution of CFAE in the LA also differed after antiarrhythmic drugs ( Figure 1A ).
Ablation of localized CFAE by antiarrhythmic drugs
In 28 patients who did not show AF termination just after pilsicainide, ablation of localized CFAE was performed, and terminated AF in 6 patients (AF converted to sinus rhythm in 1, focal AT in 2, perimitral flutter in 2, and typical flutter in 1). Overall, 8 patients (26.7%) in the pilsicainide group showed AF termination.
In 20 patients who did not show AF termination just after nifekalant, ablation of localized CFAE terminated AF in 8 patients (AF converted to sinus rhythm in 4, focal AT in 3, and perimitral flutter in 1) Figure 1 ). Overall, 18 patients (60%) in the nifekalant group showed AF termination. The mean number of RF applications to eliminate CFAE was 16 AE 12, and the total procedure time was 166 AE 29 minutes.
In the pilsicainide group, after a single ablation procedure, neither of 2 patients with AF termination just after pilsicainide showed a recurrence of AF. Three of 6 patients (50%) who showed AF termination by the ablation of localized CFAE showed a recurrence of AF. Overall, 3 of 8 patients (37.5%) with AF termination showed a recurrence of AF. In contrast, 6 of 22 patients (27.3%) without AF termination showed a recurrence of AF.
In the nifekalant group, after a single ablation procedure, only 1 of 10 patients (10%) with AF termination just after nifekalant showed a recurrence of AF. Only 1 of 8 patients (12.5%) with AF termination by ablation of localized CFAE showed a recurrence of AF. Overall, 2 of 18 patients (11.1%) with AF termination showed a recurrence of AF. In contrast, 5 of 12 patients (41.7%) without AF termination showed a recurrence of AF. Table 3 shows a comparison of the substrate characteristics in patients with and without AF termination. Patients with a longer AF duration, lower LA appendage flow, and shorter AF cycle length were less likely to show AF termination. In those patients, the LA substrate was significantly more fractionated in terms of the maximal CFAE, mean CFAE, and proportion of CFAE compared with patients with AF termination before and after antiarrhythmic drug. After a single ablation proce-E Figure 1 Termination of AF by the ablation of localized CFAE with nifekalant. A, Regional distribution of CFAE in the LA before and after nifekalant and the corresponding bipolar electrograms during AF. CFAE mapping revealed multiple CFAE sites, including the LA septum, LA anterior wall, LA appendage base, and near the mitral annulus region. Before nifekalant, both sites A and B showed CFAE, but after nifekalant only site B still showed CFAE. B, Intracardiac electrograms during AF before nifekalant. A Lasso catheter was positioned in the LA appendage. The mean AF cycle length was 136 ms. C, After nifekalant, the mean AF cycle length was prolonged to 171 ms. D, Ablation of CFAE at the anteroseptum successfully converted to atrial tachycardia. E, Ablation of the focus at the anterior LA resulted in the restoration of sinus rhythm. dure, patients with AF termination by ablation of localized CFAE had a significantly lower recurrence rate than those without AF termination despite CFAE ablation (19.2% versus 35.3%, P ¼ 0:04).
Difference in LA substrate between patients with and without AF termination
Long-term follow-up
A second ablation procedure was performed in 14 patients (23.3%), including 8 patients in the pilsicainide group and 6 patients in the nifekalant group, who showed recurrence of AF. Patients with AF termination had a lower incidence of second ablation procedure than those without AF termination (11.5% versus 36.7%, P ¼ 0:01).
At 17 AE 7 months after the last ablation procedure, 55 patients (91.6%) were free of AF: 47 (78.3%) without antiarrhythmic drugs and 8 (13.3%) with antiarrhythmic drugs.
Discussion
Box isolation and CFAE ablation
Nademanee et al. 5) described an electrogramguided approach by mapping and targeting areas of CFAE as AF perpetuators, and reported that after CFAE ablation, 87% of patients with persistent AF and 78% of patients with longstanding persistent AF were arrhythmia-free, including 11% of patients taking antiarrhythmic drugs. 9) We have provided an alternative approach for complete isolation of the posterior LA including all PVs, i.e., box isolation. 12, 13) In our previous study, with box isolation alone, 73% of the patients with persistent AF and 46% of the patients with longstanding persistent AF were arrhythmia-free without antiarrhythmic drugs. 13) In these successful patients, CFAE ablation was not necessary even if CFAE was present. In the remaining patients who show recurrence of AF, CFAE ablation may improve the success rate. However, it is difficult to identify patients who require additional CFAE ablation. Therefore, we used antiarrhythmic drugs before CFAE ablation to reduce CFAE. A hybrid approach of box isolation plus ablation of CFAE localized with antiarrhythmic drugs is feasible and effective for decreasing the unnecessary ablation of bystander CFAE.
Effects of antiarrhythmic drugs on CFAE
Nademanee et al. 9) used intravenous ibutilide to highlight CFAE associated with perpetuating AF after CFAE ablation, if the patient remained in AF despite the elimination of all visible CFAE. They demonstrated that the ablation of CFAE resulted in the termination of AF in 95% of the patients, however, 28% required concomitant ibutilide treatment. 7) In contrast, we used antiarrhythmic drugs before CFAE ablation. Although antiarrhythmic drugs might eliminate not only bystander CFAE but also culprit CFAE, 11 of the 12 patients with AF In our previous study of CFAE ablation without antiarrhythmic drugs, 30% of the patients with persistent or permanent AF had a recurrence of AF. 14) In contrast, in the present study, 19% of the patients who showed AF termination by CFAE ablation with antiarrhythmic drugs had a recurrence of AF. Thus, a recurrence rate of CFAE ablation with antiarrhythmic drugs was not higher than that of CFAE ablation without antiarrhythmic drugs. Therefore, additional ablation of CFAE may not be necessary when antiarrhythmic drugs terminate AF after box isolation, and ablation of only CFAEs localized with antiarrhythmic drugs may be sufficient for clinical efficacy.
Effects of Na þ channel blocker versus I Kr channel blocker on CFAE Pilsicainide has pure Na þ channel blocking action with slow recovery kinetics. 15) Nifekalant is a comparatively pure I Kr channel blocker. 16) Both pilsicainide and nifekalant similarly reduced CFAE by prolonging the AF cycle length in non-driver atrial tissue, probably due to the modification of refractoriness and conduction properties. These drugs may block fibrillatory conduction from focal drivers and eliminate some CFAE.
We previously compared the effects of pilsicainide and nifekalant on the electrophysiological properties of PV and LA in patients with AF. 17) Pilsicainide mainly prolonged the conduction time within the PV rather than LA, [18] [19] [20] whereas nifekalant did not change the conduction time. Nifekalant mainly prolonged the effective refractory period of LA rather than PV. Therefore, after box isolation, nifekalant may have a greater effect on atrial tissue outside the box than pilsicainide. Na þ channels are down-regulated by electrical remodeling in persistent AF, whereas K þ channels are not disturbed. 21) This may help to explain why nifekalant has a greater effect on AF termination than pilsicainide in persistent AF.
Clinical implications
The endpoints of CFAE ablation are either the termination of AF or the elimination of all CFAE. However, this often requires a very long procedure and extensive CFAE ablation is associated with procedural complications. Lin et al. 22) demonstrated that PV isolation eliminated some CFAE, and therefore complete PV isolation should be performed before CFAE ablation to avoid unnecessary substrate modification. However, in persistent or longstanding persistent AF, a long procedure is often needed to achieve the endpoints of CFAE ablation even after PV isolation. This study demonstrated that antiarrhythmic drugs localized CFAE and ablation of these CFAE was sufficient for clinical efficacy.
Limitations
First, the density of the mapping sites may not have been high enough.
Second, the results of this study are in part based on the effect of an antiarrhythmic drug and the ablation of CFAE after box isolation. Therefore, the cumulative effects may have led to the termination of AF.
Conclusions
Both pilsicainide and nifekalant reduce CFAE, and nifekalant had a greater effect on AF termination than pilsicainide. After a single ablation procedure, patients with AF termination by ablation of localized CFAE had a lower recurrence rate than those without AF termination despite CFAE ablation. Ablation of only CFAEs localized with antiarrhythmic drugs may be sufficient for clinical efficacy in the patients with persistent or longstanding persistent AF.
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